Ann: Race Appoints George Clinical for Phase 1 Trial of RC220, page-115

TBH looking at the full paper I didn't find the abstract to be as discrepant as some seem to think. Yes the abstract could have been better worded but the final conclusion of doxo having greatest activity (i.e based on response rate) but most toxicity is sort of accurate. The response rates quoted in the abstract are not wrong but it's agreed it didn't translate into survival advantage for doxo vs bis. Actually the paper ends by trashing mitoxantrone, if anything that's the dud, not bisantrene, and perhaps that should have been made clearer rather than implying mito and bis were on a par. All my opinion/interpretation of course.